Acquired by Astra Zeneca in Jul 2024
FUSN - Fusion Pharmaceuticals Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Hamilton,
Canada
Type: Equity
FUSN price evolution
FUSN
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $29.11 | $62.77 | $28.11 | $33.29 |
| Short term investments | $182.74 | $172.15 | $164.56 | $166.07 |
| Net receivables | $6.21 | $0.01 | $0.04 | $0.06 |
| Inventory | ||||
| Total current assets | $220.92 | $243.4 | $203.26 | $207.86 |
| Long term investments | $72.58 | $13.73 | $15.93 | $28.42 |
| Property, plant & equipment | $24.45 | $23.9 | $24.98 | $23.34 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $102.9 | $42.44 | $50.11 | $60.43 |
| Total investments | $255.32 | $185.89 | $180.49 | $194.5 |
| Total assets | $323.81 | $285.84 | $253.38 | $268.29 |
| Current liabilities | ||||
| Accounts payable | $2.5 | $1.86 | $1.06 | $2.06 |
| Deferred revenue | $1 | $1 | $1 | $3 |
| Short long term debt | $4.29 | $4.16 | $6.17 | $5.36 |
| Total current liabilities | $20.76 | $16.22 | $17.48 | $17.09 |
| Long term debt | $60.26 | $46.17 | $46.46 | $45.27 |
| Total noncurrent liabilities | $61.23 | $47.14 | $47.43 | $48.23 |
| Total debt | $64.55 | $50.33 | $52.63 | $50.62 |
| Total liabilities | $81.98 | $63.36 | $64.91 | $65.33 |
| Shareholders' equity | ||||
| Retained earnings | -$410.43 | -$376.76 | -$348.58 | -$331.33 |
| Other shareholder equity | -$0.58 | $0.24 | -$0.84 | -$0.25 |
| Total shareholder equity | $241.83 | $222.48 | $188.47 | $202.96 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $62.77 | $43.86 | $54.79 | $92.41 |
| Short term investments | $172.15 | $127.01 | $147.9 | $131.88 |
| Net receivables | $0.01 | $1.72 | $0.36 | $0.8 |
| Inventory | ||||
| Total current assets | $243.4 | $179 | $211.76 | $228.16 |
| Long term investments | $13.73 | $15.76 | $19.99 | $77.08 |
| Property, plant & equipment | $23.9 | $10.31 | $9.45 | $1.97 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $42.44 | $40.07 | $40.51 | $82.51 |
| Total investments | $185.89 | $142.77 | $167.88 | $208.96 |
| Total assets | $285.84 | $219.06 | $252.27 | $310.68 |
| Current liabilities | ||||
| Accounts payable | $1.86 | $2.69 | $2.19 | $3.4 |
| Deferred revenue | $1 | $3 | $4.04 | $5 |
| Short long term debt | $4.16 | $1.44 | $1.22 | |
| Total current liabilities | $16.22 | $15.07 | $12.51 | $11.86 |
| Long term debt | $46.17 | $34.23 | $5.51 | |
| Total noncurrent liabilities | $47.14 | $41.78 | $8.3 | $4.31 |
| Total debt | $50.33 | $40.25 | $6.72 | |
| Total liabilities | $63.36 | $56.84 | $20.82 | $16.16 |
| Shareholders' equity | ||||
| Retained earnings | -$376.76 | -$281.86 | -$194.25 | -$113.2 |
| Other shareholder equity | $0.24 | -$0.47 | -$0.12 | $0.04 |
| Total shareholder equity | $222.48 | $162.22 | $231.46 | $294.51 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.01 | $0.03 | ||
| Cost of revenue | ||||
| Gross Profit | $2.01 | $0.03 | ||
| Operating activities | ||||
| Research & development | $21.31 | $20.65 | $14.59 | $18.99 |
| Selling, general & administrative | $14.55 | $7.63 | $6.81 | $7.75 |
| Total operating expenses | $35.86 | $28.27 | $21.39 | $26.75 |
| Operating income | -$35.86 | -$28.27 | -$19.39 | -$26.71 |
| Income from continuing operations | ||||
| EBIT | -$32.05 | -$25.55 | -$16.18 | -$24.14 |
| Income tax expense | -$0.24 | $1.3 | -$0.25 | -$0.24 |
| Interest expense | $1.85 | $1.34 | $1.32 | $1.28 |
| Net income | ||||
| Net income | -$33.67 | -$28.18 | -$17.25 | -$25.18 |
| Income (for common shares) | -$33.67 | -$28.18 | -$17.25 | -$25.18 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.07 | $1.46 | $1.44 | |
| Cost of revenue | ||||
| Gross Profit | $2.07 | $1.46 | $1.44 | |
| Operating activities | ||||
| Research & development | $70.1 | $58.9 | $56.36 | $17.19 |
| Selling, general & administrative | $31.2 | $30.6 | $27.1 | $20.74 |
| Total operating expenses | $101.3 | $89.5 | $83.45 | $37.94 |
| Operating income | -$99.23 | -$88.03 | -$82.02 | -$37.94 |
| Income from continuing operations | ||||
| EBIT | -$88.94 | -$87.65 | -$81.17 | -$75.39 |
| Income tax expense | $0.79 | -$1.84 | -$0.12 | $2.61 |
| Interest expense | $5.17 | $1.8 | $0.33 | |
| Net income | ||||
| Net income | -$94.9 | -$87.61 | -$81.05 | -$78.33 |
| Income (for common shares) | -$94.9 | -$87.61 | -$81.05 | -$79.72 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Net income | -$33.67 | -$28.18 | -$17.25 | -$25.18 |
| Operating activities | ||||
| Depreciation | $1.22 | $1.21 | $1.04 | $0.93 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $4.52 | $3.25 | $2.99 | $3.05 |
| Total cash flows from operations | -$27.31 | -$17.94 | -$18.84 | -$19.58 |
| Investing activities | ||||
| Capital expenditures | -$1.33 | -$1.48 | -$0.47 | -$0.71 |
| Investments | -$69.04 | -$3.76 | $13.8 | -$25.61 |
| Total cash flows from investing | -$70.37 | -$5.24 | $13.33 | -$26.32 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $49.1 | $57.85 | $0.36 | $24.45 |
| Net borrowings | $14.91 | |||
| Total cash flows from financing | $64.01 | $57.85 | $0.33 | $24.31 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$33.67 | $34.67 | -$5.18 | -$21.59 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$94.9 | -$87.61 | -$81.05 | -$78.33 |
| Operating activities | ||||
| Depreciation | $3.86 | $2.05 | $1.71 | $0.48 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $12.44 | $10.84 | $8.6 | $3.37 |
| Total cash flows from operations | -$81.8 | -$73.28 | -$75.74 | -$29.77 |
| Investing activities | ||||
| Capital expenditures | -$3.89 | -$2.14 | -$1.49 | -$1.12 |
| Investments | -$38.87 | $25.23 | $39.27 | -$209.33 |
| Total cash flows from investing | -$42.76 | $23.09 | $37.77 | -$210.45 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $146.04 | $6.04 | $0.62 | $197.68 |
| Net borrowings | $34.69 | |||
| Total cash flows from financing | $142.01 | $40.73 | $0.35 | $265.51 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $17.44 | -$9.46 | -$37.62 | $25.29 |
News
Fundamentals
| Market cap | $1.83B |
|---|---|
| Enterprise value | $1.86B |
| Shares outstanding | 84.87M |
| Revenue | $2.04M |
|---|---|
| EBITDA | -$93.51M |
| EBIT | -$97.92M |
| Net Income | -$104.28M |
| Revenue Q/Q | -100.00% |
| Revenue Y/Y | 125.66% |
| P/E ratio | -17.54 |
|---|---|
| EV/Sales | 913.86 |
| EV/EBITDA | -19.94 |
| EV/EBIT | -19.04 |
| P/S ratio | 896.49 |
| P/B ratio | 7.54 |
| Book/Share | 2.86 |
| Cash/Share | 0.34 |
| EPS | -$1.23 |
|---|---|
| ROA | -36.87% |
| ROE | -48.74% |
| Debt/Equity | 0.28 |
|---|---|
| Net debt/EBITDA | -0.57 |
| Current ratio | 10.64 |
| Quick ratio | 10.64 |